0
0
Metsera Inc., a clinical-stage biotechnology company focused on obesity treatments, recently announced highly encouraging results from its mid-stage clinical trials of its investigational obesity drug, MET-097i. This injectable drug, engineered to activate the GLP-1 receptor, showed significant weight loss and good tolerability in people with obesity, according to data released on September 29, 2025. The findings mark an important advance in the growing field of obesity therapeutics and have drawn considerable attention, including from pharmaceutical giant Pfizer, which is acquiring Metsera for up to $7.3 billion to accelerate the drug’s development and market entry.
Key Trial Outcomes: Significant Weight Loss and Favorable Tolerability
MET-097i is an ultra-long-acting GLP-1 receptor agonist designed for extended dosing intervals, potentially offering monthly or weekly administration options. In the VESPER-1 Phase 2b trial, participants receiving weekly doses of MET-097i experienced a mean placebo-subtracted weight loss of up to 14.1% after 28 weeks, with no weight loss plateau observed. In VESPER-3, which included dose titration steps, MET-097i showed an excellent tolerability profile characterized by minimal gastrointestinal side effects—13% nausea and 11% vomiting, with diarrhea occurrences similar to placebo. Importantly, study retention was high (97.1%), reflecting good patient adherence to the regimen.
Earlier Phase 2a data also indicated a dose-dependent weight loss effect with up to 11.3% placebo-adjusted reduction after 12 weeks and individual patients in the highest dose cohort achieving nearly 20% reduction. Most reported adverse events were mild gastrointestinal symptoms tending to resolve quickly, particularly after the first week of dosing.
Expert Insights
Dr. Steve Marso, Chief Medical Officer of Metsera, highlighted the dual benefit of MET-097i as “a first- and best-in-class ultra-long acting nutrient-stimulated hormone analog, delivering competitive efficacy with category-leading scalability, tolerability, and convenience.” He emphasized the potential to advance MET-097i as a foundational monotherapy peptide and in combination regimens, supported by the drug’s capacity for flexible dosing intervals and favorable safety profile.
Independent experts not involved in the study praised the results for their clinical significance and potential impact. An Evercore ISI analyst described the outcomes as “solid,” suggesting the drug could become a significant addition to the obesity treatment landscape when considering its efficacy and prolonged dosing schedule. Physicians note that prolonged dosing intervals could improve patient adherence compared to existing weekly injectable therapies.
Context and Background
Obesity is a major public health challenge worldwide, linked to increased risks for diabetes, cardiovascular disease, and other chronic conditions. GLP-1 receptor agonists have become a cornerstone in medical obesity management due to their effectiveness in reducing appetite and improving metabolic parameters. However, current therapies, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, usually require weekly injections, which some patients find burdensome.
Metsera employs a proprietary technology known as Half-Life Optimization by Lipid Optimization (HALO), enabling peptides like MET-097i to bind to albumin in the blood and achieve half-lives approaching three weeks. This technological advance supports less frequent dosing schedules, which could enhance convenience and adherence, important factors for long-term obesity management success.
Implications for Public Health and Patient Care
The introduction of MET-097i and other drugs in Metsera’s pipeline, including an amylin-targeting candidate with preliminary data showing up to 8.4% placebo-adjusted weight loss, could expand treatment options beyond currently available GLP-1 agonists. Better tolerability, longer dosing intervals, and potential combination therapies might help more people achieve and maintain significant weight loss, reducing obesity-related health burdens at the population level.
For individual patients, these findings highlight potential new tools that could ease daily treatment routines, minimize side effects, and increase sustained engagement with weight loss therapies. However, lifestyle interventions, including diet and physical activity, remain foundational components for successful obesity management.
Limitations and Considerations
While the trial results are promising, it is important to note that mid-stage clinical trials involve relatively limited participant numbers and durations. Longer-term studies involving more diverse populations are needed to fully assess sustained efficacy, safety, and real-world adherence. Additionally, gastrointestinal side effects, while generally mild and transient, could still impact patient comfort and continuation of therapy.
Ongoing Phase 3 trials will provide further clarity on these aspects and support regulatory approval processes. Given this is investigational treatment, MET-097i is not yet available clinically, and patients should consult healthcare professionals for current standard obesity treatments.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
